By 2023, it is projected that CMO/CDMO Industry Analysis in Brazil would expand by US$ 697.93 million. For the projection period (2023 to 2033), a compound annual growth rate (CAGR) of 2.7% is anticipated. It is anticipated that the company will be worth roughly US$ 907.67 million by 2033.
The contract manufacturing organization (CMO) and contract development and manufacturing organization (CDMO) space in Brazil is a dynamic and rapidly evolving sector in the pharmaceutical and biotechnology businesses. Brazil, one of the leading pharmaceutical ecosystems in Latin America, offers significant opportunities and challenges for CMOs and CDMOs.
Unlock Peak Performance - Get Your Sample Now:
https://www.futuremarketinsights.com/reports/sample/rep-gb-18061
The pharmaceutical sector in Brazil has been expanding rapidly in recent years, driven by factors such as an aging population, increased healthcare access, and a growing middle class. This growth has translated into a rising demand for pharmaceutical products and manufacturing services, making Brazil an attractive destination for CMOs and CDMOs.
The Brazilian Health Regulatory Agency (ANVISA) enforces strict regulatory standards for pharmaceutical manufacturing. CMOs and CDMOs that can navigate and assist clients in meeting these regulatory requirements gain a competitive advantage in the business.
To operate effectively in Brazil, pharmaceutical companies are often required to have a local manufacturing presence. This has led to collaborations and partnerships with local CMOs and CDMOs, both domestic and international.
Brazil’s pharmaceutical landscape is increasingly focusing on biotechnology, including the development of biologics, biosimilars, and advanced therapies. CMOs and CDMOs with expertise in biomanufacturing are well-positioned to cater to this growing segment.
Key Takeaways:
- By service, the stand-alone service segment is expected to hold a share of 46.2% and surge at a CAGR of 3.4% by 2033.
- By product, the API substrate segment is anticipated to showcase a lucrative CAGR of 1.9% from 2023 to 2033.
- By expression system, the mammalian segment will likely exhibit a CAGR of 2.7% in the estimated period.
- By company size, the mid-sized companies segment is anticipated to record a CAGR of 2.3% in the evaluation period.
- By the scale of operation, the commercial segment is estimated to register a CAGR of 2.9% from 2023 to 2033.
- Southeast Brazil is considered to be the leading region with a value share of 68.6% at the end of the forecast period.
“With rising drug development complexity, specializing in specific therapeutic areas, and high-quality manufacturing, the Brazil CMO/CDMO business is expected to witness an advancement over the forecast period,” opines Sabyasachi Ghosh Associate Vice President at Future Market Insights (FMI).
Competitive Landscape:
Expansion and acquisition among leading companies or brands is the key strategy of manufacturers of the ecosystem, such as Catalent and Fragon, among others. They aim to enhance their presence in the business and compete with other firms during the forecast period. Following are a few examples of the latest developments:
- In February 2022, Pharma Nobis, LLC completed its acquisition of Fagron’s contract manufacturing business and manufacturing facility.
- In August 2022, Catalent made an announcement regarding its acquisition of Metrics Contract Services. Metrics Contract Services is a specialized Contract Development and Manufacturing Organization (CDMO) known for its 333,000-square-foot facility located in Greenville.
Brazil CMO/CDMO Industry Outlook by Category:
By Services:
- Stand-alone Services
- Cell Line Development
- Development and Bio Manufacturing
- Analytical Services
- Fill Finish
- Packaging
- Clinical Supply Services
- Integrated Development
- Scale-up and Tech Transfer
- Technology and Innovation
- Quality Control and Quality Assurance
- Regulatory Assistance
By Product:
- API Substrate
- Large Molecule
- Monoclonal Antibodies
- Antibody Fragments
- Recombinant Therapeutic Proteins
- Viral Vector
- Cell and Gene Therapy
- Vaccine
- Peptides
- Antibody Drug Conjugates (ADCs)
- Small Molecule
By Expression System:
- Mammalian
- Microbial
- Bacteria
- Yeast
By Company Size:
- Small
- Mid-sized
- Large
- Very Large
By Scale of Operation:
- Preclinical
- Clinical
- Phase I
- Phase II
- Phase III
- Commercial
